MSS
TEVA icon

Mitchell Sinkler & Starr’s Teva Pharmaceuticals TEVA Stock Holding History

Mitchell Sinkler & Starr’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-11,218
Closed -$439K – 131
2013
Q2 		$439K Buy
+11,218
New +$437K 0.1% 124

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Mitchell Sinkler & Starr's TEVA Position: Q3 2013 in Review

Mitchell Sinkler & Starr sold out of Teva Pharmaceuticals (TEVA) in Q3 2013, closing a stake of 11,218 shares — an estimated $439K sold.

Mitchell Sinkler & Starr first reported a position in TEVA in Q2 2013 and held it in 1 quarter. The position peaked at $439K in Q2 2013. 705 funds tracked by Wall St. Rank hold TEVA as of Q3 2013.

  • Mitchell Sinkler & Starr reported no remaining Teva Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Mitchell Sinkler & Starr sold 11,218 Teva Pharmaceuticals shares in Q3 2013, an estimated $439K.
  • Mitchell Sinkler & Starr first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Mitchell Sinkler & Starr's Teva Pharmaceuticals position peaked at $439K in Q2 2013.
  • 705 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2013.

Based on Mitchell Sinkler & Starr's 13F filing for Q3 2013, filed 22 Oct 2013.